E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS.
Babiker HM, et al.
Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28.
Invest New Drugs. 2019.
PMID: 30264293
Free PMC article.
Clinical Trial.